Nucleic Acid Vaccination against HIV-1

  • Ami R. Shah
  • David B. Weiner
  • Jean D. Boyer
Part of the Infectious Agents and Pathogenesis book series (IAPA)


Simian Immunodeficiency Virus Genetic Immunization Recombinant Gp160 Protein Major Histocompatibility Class Class Envelope Construct 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    HIV/AIDS, 1996, UNAIDS Fact Sheet, UNAIDS/WHO.Google Scholar
  2. 2.
    Ho, D. D., 1996, Therapy of HIV infections: Problems and prospects, Bull. N. Y. Acad. Med. 73:37–45.PubMedGoogle Scholar
  3. 3.
    Walker, B. D., 1994, The rationale for immunotherapy in HIV-1 infection, J. Acquired Immune Defic. Syndr. 7:S6–S13.Google Scholar
  4. 4.
    Cao, Y., Qin, L., Zhang, L., Safrit, J., and Ho, D. D., 1995, Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type-1 infection, N. Engl. J. Med. 332:201–208.CrossRefPubMedGoogle Scholar
  5. 5.
    Ugen, K. E., Srikantan, V., Goedert, J. J., Nelson, R. P., Williams, W. V., and Weiner, D. B., 1997, Vertical transmission of immunodeficiency virus type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope, J. Infect. Dis. 175:63–69.PubMedGoogle Scholar
  6. 6.
    Ugen, K. E., Goedert, J. J., Boyer, J., Refaeli, Y., Frank, I., Williams, W. V., Willoughby, A., Landesman, S., Mendez, H., Rubinstein, A., Kieber-Emmons, T., and Weiner, D. B., 1992, Vertical transmission of HIV infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1, J. Clin. Invest. 89:1923–1930.PubMedCrossRefGoogle Scholar
  7. 7.
    Rossi, P., Moschese, V., Broliden, P., Fundaro, C., Quintl, I., Plebani, A., Giaquinto, C., Tovo, P. A., Ljunggren, K., Rosen, J., Wigzell, H., Jondal, M., and Wahren, B, 1989, Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers, Proc. Natl. Acad. Sci. USA 86:8055–8058.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheingsong-Papov, R., Callow, D., Beddows, S., Shaunak, S., Wasi, C., Kaleebu, P., Gilks, C., Petrascu, I. V., Garaev, M. M., Watts, D. M., et al., 1992, Geographic diversity of human immunodeficiency virus type-1: Serologic reactivity to env envelopes and relationship to neutralization, J. Infect. Dis. 165:256–261.Google Scholar
  9. 9.
    Emini, E., Schleif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshi, S., Putney, S. D., Matsushita, S., Cobb, K. E., Jett, C. M., et al., 1992, Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody, Nature 355:728–730.CrossRefPubMedGoogle Scholar
  10. 10.
    Putkonen, P., Thorstensson, R., Ghavamzadeh, L., Albert, J., Hild, K., Bibefeld, G., and Norrby, E., 1991, Prevention of HIV-2 and SIVSM infection by passive immunization in cynomolgus monkeys, Nature 352:436–438.CrossRefPubMedGoogle Scholar
  11. 11.
    Graham, B., and Wright, P. F., 1995, CandidateAlDSvaccines, N. Engl.J. Med. 33:1331–1339.CrossRefGoogle Scholar
  12. 12.
    Schwartz, D., Gorse, G., Clements, M. L., Belshe, R., Izu, A., Duliege, A. M., Berman, P., Twaddell, T., Stablein, D., Sposto, R., Siliciano, R., and Matthews, T., 1993, Induction of HIV-1 neutralising and syncytium-inhibiting antibodies of uninfected recipients of HIV-1 (IIIB) rgp 120 subunit vaccine, Lancet 342:69–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Berman, P., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., and Eichberg, J. W., 1990, Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160, Nature 345:622–625.CrossRefPubMedGoogle Scholar
  14. 14.
    Bruck, C., Thiriat, C., Delers, A., et al., 1993, Comparison of vaccine protection in chimpanzees immunized with two different forms of recombinant HIV-1 envelope glycoprotein, AIDS Res. Hum. Retrovir. 9:S110.Google Scholar
  15. 15.
    Girard, M., Meigner, B., Barre-Sinoussi, F., Kieny, M. P., Matthews, T., Muchmore, E., Nara, P. L., Wei, Q,, Rimsky, L., Weinhold, K., and Fultz, P. N., 1995, Vaccine-induced protection against infection by heterologous regions in human immunodeficiency virus type-1, J. Virol. 69:6239–6248.PubMedGoogle Scholar
  16. 16.
    Pinto, L., Sullivan, J., Berzofsky, J. A., Clerici, M., Kessler, H. A., Landay, A. L., and Shearer, G. M., 1995, Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids, J. Clin. Invest. 96:867–876.PubMedCrossRefGoogle Scholar
  17. 17.
    Rowland-Jones, S., Sutton, J., Ariyoshi, K., Dong, T., Gotch, F., McAdam, S., Whitby, D., Sabally, S., Allimore, A., Corrah, T., Takiguchi, M., McMichael, A., and Whittle, H., 1995, HIV-specific T-cells in HIV-exposed but uninfected Gambian women, Nature Med. 1:59–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B., 1994, Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type-I infection, J. Virol. 68:6103–6110.PubMedGoogle Scholar
  19. 19.
    Koup, R., Safrit, J. T., Cao, Y., et al., 1994, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency type-I syndrome, J. Virol. 64:621–629.Google Scholar
  20. 20.
    Hulskotte, E. G., Geretti, A. M., Siebelink, K. H., van Amerongen, G., Cranage, M. P., Rud, E. W., Norley, S. G., de Vries, P., and Osterhaus, A. D., 1995, Vaccine-induced virus neutralizing antibodies and cytotoxic T cells do not protectom experimental infection with simian immunodeficiency virus SIVmac32H5), J. Virol. 69:6289–6296.PubMedGoogle Scholar
  21. 21.
    Rosenberg, E. S., Billings, J. M., Caliendo, A. M., et al., 1997, Vigorous HIV-1 specific CD4 T cell responses associated with control of viremia, Science 278:1447–1450.CrossRefPubMedGoogle Scholar
  22. 22.
    Cocchi, R., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P., 1995, Identification of RANTES, MIP-1 alpha and MIP-1 beta as the major HIV-1 suppressive factors produced by CD8+ T cells, Science 270:1811–1815.PubMedCrossRefGoogle Scholar
  23. 23.
    Walker, C. M., Moody, D. J., Stites, D. P., and Levy, J. A., 1989, CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication, Science 66:1663–1666.Google Scholar
  24. 24.
    Mackewicz, C. E., Ortega, H. W., and Levy, J. A., 1991, CD8 activity correlates with the clinical state of the infected individual, J. Clin. Invest. 87:1462–1466.PubMedCrossRefGoogle Scholar
  25. 25.
    Heeney, J. L., Teeuwsen, V. J., van Gils, M., Bogers, W. M., DeGiuli Morghen, C., Radaelli, A., Barnett, S., Morein, B., Akerblom, L., Wang, Y., Lehner, T., and David, D., 1998, Beta chemokines and neutralizing antigenicity titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques, Proc. Natl. Acad. Sci. USA 18:10803–10808.CrossRefGoogle Scholar
  26. 26.
    Malim, M., Hauber, J., Le, S. Y., Maizil, J. V., and Cullen, B. R., 1989, The HIV-1 rev trans activator acts through a structured target sequence to activate a nuclear export of unspliced viral mRNA, Nature 338:254–257.CrossRefPubMedGoogle Scholar
  27. 27.
    Fan, L., and Peden, K., 1992, Cell-free transmission of vif-mutants of HIV-1, Virology 190: 19–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Gabduza, D., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W., and Sodrowski, J., 1992, Role of vif in replication of human immunodeficiency virus type-1 transmission in CD4+ lymphocytes, J. Virol. 66:6489–6495.Google Scholar
  29. 29.
    Von Schwedler, U., Song, J., Aiken, C., and Trono, D., 1993, Vif is crucial for human immunodeficiency virus type-1 proviral DNA synthesis in infected cells, J Virol. 67:4945–4955.Google Scholar
  30. 30.
    Klimkait, T., Strebel, K., Hoggan, M. D., Martin, M. A., and Orenstein, J. M., 1990, The human immunodeficiency virus type-1 specific protein Vpu is required for efficient virus mutation and release, J. Virol. 64:621–629.PubMedGoogle Scholar
  31. 31.
    Levy, D. N., Fernandes, L. S., Williams, W. V., and Weiner, D. B., 1993, Induction of cell differentiation by human immunodeficiency virus-1 Vpr, Cell 72:541–550.CrossRefPubMedGoogle Scholar
  32. 32.
    Levy, D. N., Refaeli, Y., MacGregor, R. R., and Weiner, D. B., 1994, Serum Vpr regulates productive infection and latency of human immunodeficiency virus type-1, Proc. Natl. Acad. Sci. USA 91:10873.PubMedCrossRefGoogle Scholar
  33. 33.
    Levy, D. N., Refaeli, Y., and Weiner, D. B., 1994, Extracellular Vpr protein increases cellular permissiveness to HIV replication and reactivates virus from latency, J. Virol. 69:1243–1252.Google Scholar
  34. 34.
    Kim, S., Ikeuchi, K., Bym, R., Groopman, J., and Baltimore, D., 1989, Lack of negative influence on viral growth by the nefgene of human immunodeficiency virus type-1, Proc. Natl. Acad. Sci. USA 86:9544–9548.PubMedCrossRefGoogle Scholar
  35. 35.
    Kestler, H., Ringler, D. J., Mori, K., Panicalli, D. L., Sehgai, P. K., Daniel, M. D., and Desrosiers, R. C., 1991, Importance of the nefgene for maintenance of high virus loads and the development of AIDS, Cell 65:651–662.PubMedCrossRefGoogle Scholar
  36. 36.
    Ayyavoo, V., Nagashunmugan, N., Boyer, J., Mahalingam, S., Fernandes, L. S., LePhong, L. J., Hgun, C., Chattergoon, M., Goedert, J. J., Friedman, H., and Weiner, D. B., 1997, Development of genetic vaccines for pathogenic gene construction of attenuated vif immunization cassettes, AIDS 11:1433–1444.PubMedCrossRefGoogle Scholar
  37. 37.
    Tang, D., Devit, M., and Johnston, S. A., 1992, Genetic immunization is a simple method for eliciting an immune response, Nature 356:152–154.CrossRefPubMedGoogle Scholar
  38. 38.
    Ulmer, J., Donnelly, J,, Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. L., et al., 1993, Heterologous protection against influenza by injection of a DNA encoding a viral protein Science 259:1745–1749.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang, B., Ugen, K. E., Srikantan, V., Agadjanyan, M. G., Dang, K., Refaeli, Y., Sato, A. I., Boyer, J. D., Williams, W. V., and Weiner, D. B., 1993, Gene inoculation generates immune responses against human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. USA 90:4156–4160.PubMedCrossRefGoogle Scholar
  40. 40.
    Davis, H., Michel, M. L., and Whalen, R. G., 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, Hum. Mol. Genet. 2:1847–1851.PubMedCrossRefGoogle Scholar
  41. 41.
    Cohen, A., Boyer, J. D., and Weiner, D. B., 1998, DNA vaccination, FASEB 12:1611–1626.Google Scholar
  42. 42.
    Chattergoon, M., Robinson, T., Boyer, J. D., and Weiner, D. B., 1998, Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages, J. Immunol. 169:5707–5718.Google Scholar
  43. 43.
    Corr, M., Lee, D. J., Carson, D. A., and Tighe, H., 1996, Gene vaccination with naked plasmid DNA Mechanisms of CTL priming, J. Exp. Med. 184:1555–1560.CrossRefPubMedGoogle Scholar
  44. 44.
    Bagarazzi, M. L., Boyer, J. D., Ayyavoo, V., and Weiner, D. B., 1998, Nucleic acid based vaccines as an approach to immunization against human immunodeficiency virus type 1, Curr. Top. Microbiol. Immunol. 226:107–144.PubMedGoogle Scholar
  45. 45.
    Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R., and Robinson, H. L., 1995, Use of DNA expressing HIV-1 env and non-infectious HIV-1 particles to raise antibody responses in mice, Virology 209:147–154.CrossRefPubMedGoogle Scholar
  46. 46.
    Okuda, K., Bukawa, H., Hamajima, K., Kawamoto, S., Sekigawa, K. I., Yamada, Y., Tanaka, S. I., Ishii, N., Aoki, I., Nakamura, M., Yamamoto, H., Cullen, B. R., and Fukushima, J., 1995, Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type I env and rev products, AIDS Res. Hum. Retrovir. 11: 933–943.PubMedGoogle Scholar
  47. 47.
    Haynes, J., Fuller, D. H., Eisenbraun, M. D., Ford, M. J., and Pertmner, T. M., 1994, Accell particle medicated immunization elicits humoral, cytotoxic and protective responses, AIDS Res.Hum.Retrovir. 10:S43–S45.PubMedGoogle Scholar
  48. 48.
    Wang, B., Merva, M., Dang, R, Ugen, K. E., Boyer, J. D., Williams, W. V., and Weiner, D. B., 1994, DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen expressing cells, AlDS Res. Hum. Retrovir. 10:S35–S41.Google Scholar
  49. 49.
    Wang, B., Dang, K., Agadjanyan, M. G., Srikantan, V., Li, F., Ugen, K. E., Boyer, J. D., Merva, M., Williams, W. V., and Weiner, W. V., 1997, Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site, Vaccine 15:818–820.CrossRefGoogle Scholar
  50. 50.
    Klavinskis, L. S., Gao, L., Barnfeld, C., Lehner, T., and Parker, S, 1997, Mucosal immunity with DNA-liposomecomplexes, Vaccine 15:818–820.CrossRefPubMedGoogle Scholar
  51. 51.
    Hamijima, K., Sasaki, S., Fukushima, J., Kaneko, T., Xin, K. Q., Kusoh, I., and Okuda, K., 1998, Intranasal administration of HIV-1 DNAvaccine formulated with a polymer, carboxy-methylcellulose, augments mucosal antibody production and cell-mediated immune response, Clin. Immunol. Immunopathol. 88:205–210.CrossRefGoogle Scholar
  52. 52.
    Winchell, J. M., Routray, S., Betts, P. W., Kruingen, H. J., and Silbart, L. K., 1998, Mucosal and systemic antibody response to a C4/V3 construct following DNA vaccination of rabbits via Peyers patch, J. Infect. Dis. 178:850–853.PubMedGoogle Scholar
  53. 53.
    Raz, E., Watanabe, A., Baird, S. M., Eisenberg, R. A., Parr, T. B., Lotz, M., Kipps, T. J., and Carson, D. A., 1993, Systemic immunological effects of cytokine genes injected into skeletal muscle, Proc. Natl. Acad. Sci. USA 90:4523–4527.PubMedCrossRefGoogle Scholar
  54. 54.
    Ziang, Z. Q., and Ertl, H. C. J., 1995, Manipulation of the immune response to plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines, Immunity 2: 129–137.CrossRefGoogle Scholar
  55. 55.
    Kim, J., Ayyavoo, V., Bagarazzi, M. L., Chattergoon, M. A., Dang, R, Wang, B., Boyer, J. D., and Weiner, D. B., 1997, In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen, J. Immunol. 158:816–826.PubMedGoogle Scholar
  56. 56.
    Prayaga, S. R, Ford, M. J., and Haynes, J. R., 1997, Manipulation of HIV-1 gp120 specific immune responses elicited via gene gun based DNA immunization, Vaccine 15:1349–1352.CrossRefPubMedGoogle Scholar
  57. 57.
    Kim, J. J., Nottingham, L. K., Sin, J. I., Tsai, A., Morrison, L., Dang, R, Hu, Y., Kazahaya, K., Bennett, M., Dentchev, T., Wilson, D. M., Boyer, J. D., Agadjanyan, M. G., Chalian, A. A., and Weiner, D. B., 1998, CD8+ T cellsexpressed chemokines expand and modulate antigen-specific immune responses in the periphery, J. Clin. Invest. 102:1112–1124.PubMedCrossRefGoogle Scholar
  58. 58.
    Kim, J., Bagarazzi, M. L., Trivedi, N., Hu, Y., Kazahaya, R, Wilson, D., Ciccarelli, R., Chattergoon, M., Dang, K., Mahalingam, S., Chalian, A., Agadjanyan, M. G., Boyer, J. D., Wang, B., and Weiner, D., 1997, Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes, Nature Biotechnol. 15:641–646.CrossRefGoogle Scholar
  59. 59.
    Iwaski, A., Nicla-Stiernholm, B. J., Cahn, A. K., Birinstein, N. L., and Barber, B. H., 1997, Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines, J. Immunol. 158:4591–4601.Google Scholar
  60. 60.
    Horspool, J. H., Perrin, P. J., Woodcock, J. B., Cox, J. H., June, C. H., Harlan, D. M., St. Louie, D. C., and Lee, K. P., 1998, Nucleic acid vaccine-induced immune response require CD28 costimulation and are regulated by CTL44, J.Immunol. 160:2706–2714.PubMedGoogle Scholar
  61. 61.
    Tsuji, T., Fukushima, J., Hamajima, I., Ishii, N., Aoki, I., Bukawa, H., Ishigatsubo, Y., Tani, K., Okubo, T., Dorf, M. E., and Okuda, K., 1997, HIV-1 specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine, Immunology 90:1–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Toda, S., Ishii, N., Okada, E., Kusakabe, K. I., Arai, H., Hamajima, K., Gorai, I., Nishioka, K., and Okuda, K., 1997, HIV-1 specific cell mediated immune responses induced by DNA vaccination were enhanced by mannancoated liposomes and inhibited by anti-interferon gamma antibody, Immunology 90:1–6.CrossRefGoogle Scholar
  63. 63.
    Boyer, J. D., Wang, B., Ugen, K. E., Agadjanyan, M. G., Javadian, M. A., Frost, P., Dang, R, Carrano, R. A., Ciccarelli, R., Coney, L., Williams, W. V., and Weiner, D. B., 1996, In vivo protective anti-HIV immune responses in non-human primates through DNA immunization, J. Med. Primatol. 25:242–250.PubMedGoogle Scholar
  64. 64.
    Fynan, E., Webster, R., Fuller, D., Haynes, J., Santoro, J., and Robinson, H., 1993, DNA vaccines: Protective immunizations by parenteral, mucosal and gene-gun inoculations, Proc. Natl. Acad. Sci. USA 90:11478–11482.PubMedCrossRefGoogle Scholar
  65. 65.
    Wang, B., Boyer, J., Srikantan, V., Ugen, R, Gilbert, L., Phan, C., Dang, R, Merva, M., Agadjanyan, M. G., Newman, M., Carrano, R., McCallus, D., Coney, L., Williams, W. V., and Weiner, D. B., 1995, Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in non human primates by in vivo inoculation, Virology 221: 102–112.CrossRefGoogle Scholar
  66. 66.
    Krieg, A. M., 1996, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA, J. Lab. Clin. Med. 128:128–133.CrossRefPubMedGoogle Scholar
  67. 67.
    Sato, Y., Roman, M., Tighe, H., Corr, M., Nguyen, M. D., Silverman, G. J., Lotz, M., Carson, D. A., and Raz, E., 1996, Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, Science 273:352–354.PubMedCrossRefGoogle Scholar
  68. 68.
    Klinman, D. M., Yamshchikov, G., and Ishigatsubo, Y., 1997, Contribution of CpG motifs to the immunogenicity of DNA vaccines, J. Immunol. 158:3635–3639.PubMedGoogle Scholar
  69. 69.
    Leclerc, C., Deriaud, E., Rojas, M., and Whalen, R. G., 1997, The preferential induction of a Thl immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA, Cell. Immunol. 179:97–106.CrossRefPubMedGoogle Scholar
  70. 70.
    Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Renaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E., 1997, Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants, Nature Med. 3:849–854.PubMedCrossRefGoogle Scholar
  71. 71.
    Boyer, J. D., Cohen, A., Schumann, K., Nath, B., Lacy, K., Bagarazzi, M., Higgins, T., Baine, Y., Ciccarelli, R., Ginsberg, R., MacGregor, R. R., and Weiner, D. B., in press, Vaccination with seronegative volunteers with an HIV-1 env/rev DNA vaccine induces proliferation.Google Scholar
  72. 72.
    Letvin, N. L., Montefiori, D. C., Yasutomi, T., et al., 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, Proc. Natl. Acad. Sci. USA 94:9373–9383.CrossRefGoogle Scholar
  73. 73.
    Lu, S., Arthos, J., Montefiori, D. C., Yasutomi, Y., Manson, K., Mustafa, F., Johnason, E., Santoro, J. C., Wissink, J., Mullins, J. I., Haynes, J. R., Letvin, N. L., Wynand, M., and Robinson, H. L., 1996, Simian immunodeficiency virus DNA vaccine trial in macaques, J. Virol. 70:3978–3991.PubMedGoogle Scholar
  74. 74.
    Boyer, J. D., Ugen, K. E., Wang, B., Agadjanyan, M. G., Gilbert, L., Bagarazzi, M. L., Chattergoon, M. A., Frost, P., Javadian, M. A., Williams, W. V., Refaeli, Y., Ciccarelli, R. B., McCallus, D., Coney, L., and Weiner, D. B., 1997, Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination, Nature Med. 3:526–532.PubMedCrossRefGoogle Scholar
  75. 75.
    Boyer, J. D., Ugen, K. E., Chattergoon, M., Wang, B., Shah, A., Agadjanyan, M. G., Bagarazzi, M. L., Javadian, M. A., Williams, W. V., and Weiner, D. B., 1997, DNAvaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees, J. Infect. Dis. 176:1501–1509.PubMedCrossRefGoogle Scholar
  76. 76.
    Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A. C., Sandstrom, E., and Wahren, B., 1998, Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients, Lancet 351:1320–1325.CrossRefPubMedGoogle Scholar
  77. 77.
    MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J., Ciccarelli, R. B., Coney, L. R., Ginsberg, R. S., and Weiner, D. B., 1998, First human trial of a DNA-based vaccine against HIV-1 infection: Safety and host responses, J. Infect. Dis. 178:92–100.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Ami R. Shah
    • 1
  • David B. Weiner
    • 2
  • Jean D. Boyer
    • 2
  1. 1.Rollins School of Public HealthEmory UniversityAtlanta
  2. 2.Stellar-Chance Laboratories, Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphia

Personalised recommendations